SG11202001379WA - Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) - Google Patents

Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)

Info

Publication number
SG11202001379WA
SG11202001379WA SG11202001379WA SG11202001379WA SG11202001379WA SG 11202001379W A SG11202001379W A SG 11202001379WA SG 11202001379W A SG11202001379W A SG 11202001379WA SG 11202001379W A SG11202001379W A SG 11202001379WA SG 11202001379W A SG11202001379W A SG 11202001379WA
Authority
SG
Singapore
Prior art keywords
nash
fgf
methods
growth factor
fibroblast growth
Prior art date
Application number
SG11202001379WA
Other languages
English (en)
Inventor
Edgar Charles
Rose Christian
Yi Luo
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202001379WA publication Critical patent/SG11202001379WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Peptides Or Proteins (AREA)
SG11202001379WA 2017-09-08 2018-09-06 Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) SG11202001379WA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762556179P 2017-09-08 2017-09-08
US201762571960P 2017-10-13 2017-10-13
US201862640211P 2018-03-08 2018-03-08
PCT/US2018/049729 WO2019051073A1 (en) 2017-09-08 2018-09-06 MODIFIED FIBROBLAST GROWTH FACTOR 21 (FGF-21) FOR USE IN NON-ALCOHOLIC STÉATOHÉPATITE (NASH) TREATMENT METHODS

Publications (1)

Publication Number Publication Date
SG11202001379WA true SG11202001379WA (en) 2020-03-30

Family

ID=63714038

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001379WA SG11202001379WA (en) 2017-09-08 2018-09-06 Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)

Country Status (12)

Country Link
US (2) US11642395B2 (de)
EP (1) EP3678686A1 (de)
JP (2) JP2020533304A (de)
KR (1) KR20200051706A (de)
CN (1) CN111050786A (de)
AU (1) AU2018329850A1 (de)
BR (1) BR112020004136A2 (de)
CA (1) CA3072903A1 (de)
IL (1) IL272976A (de)
MX (1) MX2020002206A (de)
SG (1) SG11202001379WA (de)
WO (1) WO2019051073A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230090114A1 (en) * 2020-01-31 2023-03-23 89Bio Ltd. Methods for promoting weight loss
WO2024044680A2 (en) * 2022-08-24 2024-02-29 89Bio, Inc. Methods of treatment of nash using mutant fgf-21 peptide conjugates

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
JP2002531067A (ja) 1998-10-30 2002-09-24 ノボザイムス アクティーゼルスカブ 低下したアレルゲン性を有するグリコシル化タンパク質
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1922101A (en) 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
CA2468610A1 (en) 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
DE602004011770T2 (de) 2003-06-12 2009-02-05 Eli Lilly And Co., Indianapolis Fusionsproteine
WO2005061712A1 (en) 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1727559A1 (de) 2004-01-26 2006-12-06 Eli Lilly And Company Verwendung von fgf-21 und eines thiazolidindions zur behandlung von diabetes typ 2
US20070265200A1 (en) 2004-03-17 2007-11-15 Eli Lilly And Company Glycol Linked Fgf-21 Compounds
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
SI1751184T1 (sl) 2004-05-13 2010-01-29 Lilly Co Eli Fgf-21 fuzijski proteini
EP1789443A1 (de) 2004-09-02 2007-05-30 Eli Lilly And Company Muteine des fibroblasten-wachstumsfaktors 21
DK1789442T3 (da) 2004-09-02 2009-11-16 Lilly Co Eli Muteiner af fibroblastvækstfaktor 21
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
MX341149B (es) 2008-10-10 2016-08-09 Amgen Inc Mutantes fgf21 y uso de los mismos.
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US20180099001A1 (en) * 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
CN103923207B (zh) 2014-04-08 2016-03-09 东北农业大学 一种fgf-21突变体蛋白的制备及其在治疗非酒精性脂肪肝中的应用
CN105214069A (zh) * 2014-06-04 2016-01-06 温州医科大学 成纤维细胞生长因子21在急性肝功能衰竭和酒精性脂肪肝中的应用
CN114805533A (zh) * 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
WO2016081475A1 (en) * 2014-11-17 2016-05-26 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP3712279B1 (de) * 2015-09-14 2024-03-20 Genfit Verfahren zur diagnose und beurteilung von nichtalkoholischer steatohepatitis
LT3368554T (lt) 2015-10-28 2020-09-25 Yuhan Corporation Ilgo veikimo fgf21 sulieti baltymai ir juos apimanti farmacinė kompozicija
ES2871036T3 (es) * 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares

Also Published As

Publication number Publication date
US11642395B2 (en) 2023-05-09
US20230414717A1 (en) 2023-12-28
JP2024037767A (ja) 2024-03-19
KR20200051706A (ko) 2020-05-13
EP3678686A1 (de) 2020-07-15
WO2019051073A1 (en) 2019-03-14
CN111050786A (zh) 2020-04-21
BR112020004136A2 (pt) 2020-09-08
JP2020533304A (ja) 2020-11-19
CA3072903A1 (en) 2019-03-14
US20210106653A1 (en) 2021-04-15
IL272976A (en) 2020-04-30
AU2018329850A1 (en) 2020-04-23
MX2020002206A (es) 2020-07-20

Similar Documents

Publication Publication Date Title
EP3809988C0 (de) System zur behandlung von okklusionen in körperlumen
IL282600A (en) Composition and method for health care
ZA201907158B (en) Methods and compositions for treating sleep apnea
IL282663A (en) BT1718 for use in cancer treatment
IL279748A (en) Preparation and method for treating pain
IL272596A (en) Pridopidine for use in the treatment of ALS
IL276247A (en) Methods and materials for the treatment of sleep apnea
HK1256909A1 (zh) Glp-1和其在用於治療代謝疾病的組合物中的用途
SG11202012070YA (en) Methods and compositions for preventing or treating tissue calcification
EP3468555C0 (de) Zusammensetzungen zur verwendung bei der behandlung von bakteriellen infektionen
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
IL272976A (en) Fibroblast growth factor 21 (FGF-21) is modulated for use in the treatment of fatty liver and non-alcoholic fatty liver disease (NASH)
PL3458448T3 (pl) Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby
IL267647A (en) Combined treatment of non-alcoholic steatohepatitis (nash) and liver fibrosis
HK1244012A1 (zh) 具有增强的抑制性質的抗trka抗體及其衍生物用於治療骨相關疼痛
IL275767A (en) Compositions and methods for treating metabolic diseases
IL282294A (en) Combinations for immune modulation in cancer treatment
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
IL280830A (en) Bracelets for use in cancer treatment methods
EP3708173C0 (de) Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
PL3476397T3 (pl) Nowe kompozycje i ich zastosowanie w leczeniu zakażeń bakteryjnych
SG11202002088TA (en) Methods and compositions for treating chronic lung diseases
IL271758A (en) Statin preparations and methods for use in the treatment of synuclein pathologies
IL270552A (en) Valclospoin preparation for the treatment of proteinaceous kidney disease
HK1256935A1 (zh) 使用疫苗治療癌症或皮膚病變的方法和組合物